



## Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy

Schmiegelow, Kjeld; Müller, Klaus; Mogensen, Signe Sloth; Mogensen, Pernille Rudebeck; Wolthers, Benjamin Ole; Stoltze, Ulrik Kristoffer; Tuckuviene, Ruta; Frandsen, Thomas

*Published in:*  
F1000Research

*DOI:*  
[10.12688/f1000research.10768.1](https://doi.org/10.12688/f1000research.10768.1)

*Publication date:*  
2017

*Document version*  
Publisher's PDF, also known as Version of record

*Document license:*  
[CC BY](https://creativecommons.org/licenses/by/4.0/)

*Citation for published version (APA):*  
Schmiegelow, K., Müller, K., Mogensen, S. S., Mogensen, P. R., Wolthers, B. O., Stoltze, U. K., ... Frandsen, T. (2017). Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. *F1000Research*, 6, [444]. <https://doi.org/10.12688/f1000research.10768.1>



REVIEW

# Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy [version 1; referees: 3 approved]

Kjeld Schmiegelow <sup>1,2</sup>, Klaus Müller<sup>1,2</sup>, Signe Sloth Mogensen<sup>1</sup>, Pernille Rudebeck Mogensen<sup>1,3</sup>, Benjamin Ole Wolthers<sup>1</sup>, Ulrik Kristoffer Stoltze<sup>1</sup>, Ruta Tuckuviene<sup>4</sup>, Thomas Frandsen<sup>1</sup>

<sup>1</sup>Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark  
<sup>2</sup>Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark  
<sup>3</sup>Department of Diabetes and Metabolism, University Hospital Rigshospitalet, Copenhagen, Denmark  
<sup>4</sup>Department of Pediatrics, Aalborg University Hospital, Aalborg, Denmark

**V1** **First published:** 07 Apr 2017, 6(F1000 Faculty Rev):444 (doi: 10.12688/f1000research.10768.1)  
**Latest published:** 07 Apr 2017, 6(F1000 Faculty Rev):444 (doi: 10.12688/f1000research.10768.1)

**Abstract**

During chemotherapy for childhood acute lymphoblastic leukemia, all organs can be affected by severe acute side effects, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis), thromboembolism, sinusoidal obstruction syndrome, endocrinopathies (especially steroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and across study groups there has been wide diversity in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences for different leukemia protocols. Since treatment of acute lymphoblastic leukemia now yields 5-year overall survival rates above 90%, there is a need for strategies for assessing the burden of toxicities in the overall evaluation of anti-leukemic therapy programs.

**Open Peer Review**

**Referee Status:**

	Invited Referees		
	1	2	3
<b>version 1</b> published 07 Apr 2017			

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

- 1 **Chris Halsey**, University of Glasgow UK
- 2 **Anne Uyttebroeck**, University Hospitals Leuven Belgium
- 3 **Jan Stary**, University Hospital Motol Czech Republic

**Discuss this article**

Comments (0)

**Corresponding author:** Kjeld Schmiegelow ([Kjeld.Schmiegelow@regionh.dk](mailto:Kjeld.Schmiegelow@regionh.dk))

**How to cite this article:** Schmiegelow K, Müller K, Mogensen SS *et al.* **Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy [version 1; referees: 3 approved]** *F1000Research* 2017, 6(F1000 Faculty Rev):444 (doi: [10.12688/f1000research.10768.1](https://doi.org/10.12688/f1000research.10768.1))

**Copyright:** © 2017 Schmiegelow K *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

**Grant information:** This work was supported by the Danish Cancer Society and the Danish Childhood Cancer Foundation.  
*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Competing interests:** The authors declare that they have no competing interests.

**First published:** 07 Apr 2017, 6(F1000 Faculty Rev):444 (doi: [10.12688/f1000research.10768.1](https://doi.org/10.12688/f1000research.10768.1))

## Introduction

The best contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) now yields 5-year overall survival (OS) rates above 90%, which reflects intensified chemotherapy with treatment stratification directed by the somatic mutations and early response to chemotherapy, better use of conventional anti-leukemic agents, and improved supportive care, including broad-spectrum antibiotics to combat opportunistic infections<sup>1,2</sup>. However, a significant proportion of leukemic deaths, not least for lower-risk patients, are caused by therapy rather than by the leukemia itself, and this is just the tip of the toxicity iceberg<sup>3</sup>. Nearly all patients encounter mucositis and serious, though manageable, infections, and although various other severe, acute toxicities individually have relatively low incidences, almost 50% of all patients will be affected by at least one of these<sup>4</sup>. Whereas recent high-throughput, cost-effective technologies have revolutionized our insight into the somatic mutational landscape of ALL, disease pathogenesis, and drug resistance mechanisms<sup>5</sup>, our understanding of non-infectious chemotherapy-associated acute toxicities remains limited, including how to prevent and treat them. This reflects their rarity (calling for international collaboration), diverse definitions and capture strategies across study groups, lack of tissue specimens to map pathogenesis, and uncertain associations with common germline DNA variants<sup>6,7</sup>. This review summarizes recent advancements in the exploration of non-infectious, chemotherapy-associated acute toxicities and outlines strategies for future research.

## The toxicity scenario

Every organ can be affected by acute side effects of anti-leukemic chemotherapy, the most common being opportunistic infections, mucositis, central or peripheral neuropathy (or both), bone toxicities (including osteonecrosis, ON), thromboembolism (TE), sinusoidal obstruction syndrome (SOS), endocrinopathies (especially corticosteroid-induced adrenal insufficiency and hyperglycemia), high-dose methotrexate (HD-MTX)-induced nephrotoxicity, asparaginase-associated hypersensitivity, pancreatitis, and hyperlipidemia. Other toxicities, including myopathy and some rare inflammatory toxicities (for example, epidermolysis), will not be addressed in this review.

Few of the non-infectious acute toxicities are associated with clinically useful risk factors, and comparison of their frequency across various anti-leukemic treatment programs has been hampered by wide diversities in toxicity definitions, capture strategies, and reporting, thus hampering meaningful comparisons of toxicity incidences. The toxicities have traditionally been defined and graded according to the US National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)<sup>8</sup>. However, these are generic in their grading and frequently inappropriate for children<sup>9</sup> and for the acute toxicities seen during childhood ALL therapy. Accordingly, 15 international childhood ALL study groups (Ponte di Legno Toxicity Working Group, or PTWG) have developed consensus definitions for 14 acute toxicities<sup>7</sup>.

## Mucositis

Mucositis is a debilitating adverse effect that is reported to occur in at least 40% of patients after high-dose anti-metabolites or DNA-damaging drugs, including high-dose alkylating agents given as part of conditioning therapy prior to hematopoietic stem cell transplantation (hSCT)<sup>10–13</sup>.

Risk factors for mucositis include low body weight, reduced renal function, low neutrophil counts, and elevated pre-therapeutic levels of inflammatory mediators<sup>10,12,14,15</sup>. In addition, the risk of severe mucositis has, albeit with conflicting results, been associated with common DNA polymorphisms, including the folate pathway methylenetetrahydrofolate reductase (*MTHFR*, particularly C677T)<sup>16</sup> and DNA repair<sup>17</sup>.

Oral mucositis ranges from soreness with erythema and edema to painful, ulcerative mucositis requiring narcotic analgesics, which may lead to poor nutritional status<sup>18</sup>. Intestinal mucositis typically develops in parallel with abdominal pain, diarrhea or constipation, nausea, and vomiting, but oral and intestinal mucositis may not coincide<sup>18</sup>. They both tend to peak at the time of neutrophil nadir 10 to 14 days after chemotherapy and typically resolve during the subsequent 5 to 10 days.

Gastrointestinal mucositis reflects release of damage-associated molecular patterns that are sensed by pattern recognition receptors such as Toll like-receptors, causing release of inflammatory cytokines propagating an inflammatory response<sup>19–21</sup>. This is followed by an ulceration phase and finally resolution<sup>19</sup>. The normal intestinal microbiome may play a protective role by stimulating endothelial cell proliferation and mucous production, and intestinal dysbiosis due to chemotherapy and antibiotics could aggravate mucositis, but this awaits clinical validation<sup>21–23</sup>. Severe mucositis disrupts the intestinal immunological barrier and is a risk factor for systemic infections, although it has been most intensively studied in the hSCT setting<sup>22,24</sup>. Accordingly, intestinal mucositis defined by hypocitrullinemia reflecting a reduced population of functional enterocytes may be better than neutropenia at defining the risk period for bacteremia<sup>24</sup>.

Although several studies have demonstrated temporal associations between gastrointestinal toxicity, systemic inflammation, and fever, infections can be proven in only less than 50% of febrile neutropenic episodes<sup>25,26</sup>, and the cause in microbiologically negative cases is more likely systemic inflammation—for example, C-reactive protein, interleukin-6, and *in vitro* cytokine production—than opportunistic microorganisms<sup>13,27–29</sup>. This has led to the introduction of febrile mucositis as a complementary term to the ubiquitous febrile neutropenia<sup>28</sup>. hSCT studies have linked systemic inflammation to adverse outcome and increased treatment-related mortality<sup>30,31</sup>. It is conceivable, but not yet shown, that this also holds true for ALL.

Numerous interventions have been tested for the prevention or amelioration of mucositis as reviewed and regularly updated by

the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology<sup>32</sup>. Parenteral non-steroid anti-inflammatory drugs, anti-epileptics, neuroleptics, and opioids are still the mainstay of pain control, despite often being insufficiently effective<sup>33</sup>. Probiotics containing lactobacillus species seem to reduce chemotherapy-induced diarrhea and mucositis but have been tested only in highly specific treatment settings and await formal testing in patients with chemotherapy-induced neutropenia and mucosa barrier dysfunction<sup>34–37</sup> (NCT02544685). Other less established interventions of some efficacy include intravenous glutamine, cryotherapy, recombinant keratinocyte growth factor-1, and low-level laser therapy for oral mucositis<sup>32</sup>. However, most of these approaches have been studied only insufficiently (if at all) during ALL chemotherapy.

### Central neurotoxicity

Central nervous system (CNS) toxicities during treatment occur in 10% to 15% of patients with childhood ALL and cover a wide spectrum of syndromes with overlapping symptoms, including seizures<sup>38</sup>, HD-MTX-related stroke-like syndrome (MTX-SLS)<sup>39</sup> with or without reduced consciousness, posterior reversible encephalopathy syndrome (PRES)<sup>40</sup>, and steroid psychosis<sup>41,42</sup>, and these may result in permanent or progressive neurocognitive defects (for example, attention, executive function)<sup>43–45</sup> with or without white matter changes on magnetic resonance imaging (MRI).

Corticosteroids frequently cause transient changes in sleep pattern, mood, and cognition, and this can be quite burdensome to both patients and parents<sup>46</sup>. Corticosteroids may affect the neurotransmitters dopamine or serotonin, deregulate the hypothalamic-pituitary-adrenal (HPA) axis, and cause hippocampal injury<sup>47</sup>. In general, the risk of acute, severe neurotoxicity cannot be predicted, but the risk is higher for children below six years and for treatment with dexamethasone compared with prednisolone, potentially reflecting higher CNS penetration and longer half-life in CNS of dexamethasone<sup>48–50</sup>. Germline DNA polymorphisms in genes related to drug disposition or neurogenesis or both have been associated with neurotoxicity<sup>51</sup>, but these candidate gene associations remain to be validated.

Seizures occur in approximately 10% of children with ALL<sup>38</sup>. They can occur both as an isolated symptom, together with various other CNS toxicities (for example, intracranial hemorrhage or thrombosis, PRES, or MTX-SLS), or second to electrolyte and metabolic disturbances or to infections. Many patients subsequently require long-term anti-convulsive therapy, female sex being a significant risk factor<sup>52</sup>.

MTX-SLS, which is characterized by focal neurological deficits or hemiparesis and often accompanied by disturbances in speech, affect, or consciousness (or a combination of these), develops within two to three weeks (usually 2 to 14 days) after HD-MTX or intrathecal MTX administration and waxes and wanes over the subsequent hours to days and then resolves within a few days<sup>39,53</sup>. MTX interferes with the methionine/homocysteine pathway and purine *de novo* synthesis pathways, disrupts myelin, causes accumulation of homocysteine and adenosine, and influences

neurotransmitter status with a strong excitatory effect on the N-methyl-D-aspartate receptor (NMDAR). Vitamin B<sub>12</sub> deficiency can promote these disturbances<sup>54</sup>. The incidence of SLS varies from less than 1% to 15% in the literature and appears to vary according to the scheduling and intensity of MTX and co-administration of other agents such as cyclophosphamide and Ara-C and appears more frequently in children older than 10 years<sup>39</sup>. Most patients make a full recovery, although there are reports of persisting neurological deficits, and the risk of recurrence with subsequent MTX therapy is low<sup>39</sup>. Dextromethorphan, a non-competitive antagonist to NMDAR, or aminophylline (more relevant for acute MTX-induced neurotoxicity) has been advocated on the basis of small series<sup>55,56</sup>. The effect may be dramatic, but the use of these interventions awaits formalized validation. MRI will not always be able to confirm MTX-SLS but often reveals characteristic changes allowing discrimination of MTX-SLS from PRES<sup>57</sup>.

PRES is a clinico-radiological entity frequently seen during the first months of ALL therapy, reflecting disturbances of cerebrovascular autoregulation and inconsistently characterized by headache, altered mental status, seizures, and visual disturbances<sup>40,58,59</sup>. It may have several causes, predominantly arterial hypertension, chemotherapy, and corticosteroids, but the exact cause can frequently not be determined in the individual patient<sup>58</sup>. On cranial MRI, areas of vasogenic edema are predominant but not restricted to the posterior regions of the brain or being exclusively bilateral. Affected areas are hypointense on T1-weighted and hyperintense on T2-weighted MRI<sup>59</sup>. In contrast to MTX-SLS, PRES is hyperintense on apparent diffusion-weighted coefficient MRI images.

Some patients develop frank psychosis during corticosteroid therapy<sup>41,42</sup>. There are no clear guidelines for their clinical management, but sleep medication and tranquilizers and, in severe cases, anti-psychotics (for example, risperidone) can be indicated<sup>60</sup>.

Transverse myelitis is a very rare complication seen in children with or without hematological malignancies<sup>61</sup>. It may occasionally be associated with malignant infiltration<sup>62</sup> but can also be seen as a result of intensive chemotherapy, and high-dose cytarabine, MTX, and vincristine have been suspected to play a role<sup>63</sup>.

### Peripheral neuropathy

Peripheral motor or sensory neuropathy or both are common, usually caused by vincristine, and in general completely reversible but may require many months for improvement<sup>64,65</sup>. In severe cases, they are occasionally associated with Charcot-Marie-Tooth disease<sup>66,67</sup>.

Metabolic drug-drug interactions may enhance vincristine neurotoxicity<sup>68</sup>. Vincristine is inactivated by the major drug-metabolizing CYP isoform in humans, CYP3A4, and the azoles ketoconazole, itraconazole, and posaconazole are potent inhibitors of CYP3A4<sup>69</sup>. The potency of the azoles fluconazole and voriconazole as CYP3A4 inhibitors are much lower but may be clinically significant at high doses. A few germline DNA variants and gene expression profiles have been associated with the risk of vincristine-induced neuropathy<sup>64,70</sup>.

## Bone toxicities

The pathophysiology of osteoporosis during ALL therapy is uncertain, but the leukemia itself and the use of corticosteroids may cause osteoporosis and fractures, including multifocal compression fractures of the spine<sup>71-74</sup>, and osteoporosis affects up to 20% of newly diagnosed children with ALL<sup>75</sup>. Five-year cumulative incidence of fractures has been reported to be 10% to 15% with no overall incidence difference between post-induction prednisolone or dexamethasone, although for adolescents dexamethasone seems to be associated with a higher risk<sup>73,76</sup>.

The most severe skeletal complication is symptomatic ON, caused by bone death resulting from poor blood supply<sup>77</sup>. The PTWG has published a consensus definition of ON that accounts for localization of ON, joint deformation and the impact of ON on symptoms and self-care<sup>7</sup>. If routine MRI is performed, an even higher frequency of non-symptomatic ON will be detected<sup>78</sup>. Thus, the overall reported frequency varies from less than 5% to more than 70%, and females and adolescents have the highest risk<sup>79,80</sup>. ON is mainly diagnosed during the second year of ALL therapy (that is, during maintenance therapy), although presentation can occur earlier or even after cessation of therapy<sup>78,81</sup>. Hips and knees are most commonly affected in both subclinical and clinical cases, and often multiple joints are involved<sup>77,81</sup>. Many will suffer from daily pain, decreased ability of physical activity (or even need of a wheelchair), and reduced quality of life<sup>81,82</sup>. ON can lead to joint articular surface collapse with debilitating arthritis and need for joint-preserving or joint replacement surgery during the early phase of ON or months or years later.

So far, the only proven preventive measure for ON is giving dexamethasone intermittently rather than continuously<sup>79</sup>. Corticosteroids contribute to the development of ON through osseous lipocyte hypertrophy with resultant increased pressure within the bone, which can cause vascular collapse and necrosis, and corticosteroids can cause direct toxicity to osteocytes. Fat emboli, vasculitis, or microthromboemboli that cause vascular occlusion can also contribute. Accordingly, hyperlipidemia induced by corticosteroids and asparaginase has been suggested to be associated with increased risk of ON, although most studies have been inconclusive<sup>78,83</sup>.

Genetic risk factors have been reported in pathways associated with the glutamate receptor, bone, lipid and folate metabolism, thymidylate synthase, corticosteroid disposition, and adipogenesis, but the associations have in general not been validated<sup>78,84-86</sup>.

The benefits of prognostication of ON by imaging await validation<sup>87,88</sup>. Future research should focus on potential risk factors for various grades and for single-versus-multiple site ON, on the association with metabolism of drugs that may influence lipid profiles and coagulation<sup>78</sup>, on the long-term outcome of ON, on improved guidelines for treatment adaptation and interventional surgery, and on the association of germline DNA variants with phenotype subsets.

## Thromboembolisms

TE located to the venous system is most common, and half of the cases involve the CNS<sup>89-91</sup>. The cumulative incidence of symptomatic venous TE is 2 to 8%<sup>90-93</sup>, but asymptomatic cases have been reported in up to 70% of patients<sup>92,94</sup>. Risk factors for TE include the leukemia itself, older age, central line catheters, immobilization, infections, systemic inflammation, and therapy with asparaginase or corticosteroids or both<sup>76,90,93,95,96</sup>, whereas inherited thrombophilia risk factors, including common germline DNA polymorphisms, do not seem to play a role or at best remain uncertain<sup>96</sup>. The fatality rate of venous TE is highest in children with thromboses in cerebral veins, and studies on the benefits of anti-thrombotic prophylaxis, preferably with the novel oral anti-coagulants, are needed<sup>90,97,98</sup>.

## Sinusoidal-obstruction syndrome

Until recently, SOS, previously known as veno-occlusive disease<sup>99</sup>, has primarily been a serious complication of hSCT and is otherwise rare during childhood ALL therapy except with continuous oral thioguanine<sup>100</sup>, not least in patients who carry low-activity alleles for thiopurin methyl transferase<sup>101</sup>. Doppler ultrasound showing reversed hepatic portal flow may aid the diagnosis, but a normal flow does not exclude the diagnosis and thus is not a mandatory diagnostic requirement. Instead, at least three of five criteria need to be fulfilled: that is, hepatomegaly, hyperbilirubinemia above upper normal limit (UNL), ascites, weight gain at or above 5%, and thrombocytopenia (transfusion-resistant or otherwise unexplained by treatment or both)<sup>7</sup>.

The pathogenesis remains unclear, but drug-induced damage to hepatic endothelium and microcirculation and subsequent ischemic hepatocellular necrosis are the presumed mechanism<sup>99,102,103</sup>. Previously, SOS occurred extremely rarely during 6-MP therapy<sup>100</sup> but recently has been described as a frequent complication to continuous polyethylene glycol-linked *Escherichia coli* asparaginase preparation (PEG-asparaginase) during 6-MP-based maintenance therapy when combined with pulses of either HD-MTX or vincristine/dexamethasone, probably reflecting the impact of asparaginase on 6-MP pharmacokinetics causing higher drug metabolite levels<sup>104</sup>. Management of SOS during thiopurine therapy follows the same principles as management of SOS following hSCT: that is, fluid and sodium chloride restriction, diuretics, and, in the rare severe cases, defibrotide.

## Endocrinopathies

There is a paucity of prospective longitudinal studies determining endocrine changes during ALL therapy, and the existing studies have small sample sizes. Growth retardation and relative growth hormone deficiency are common during ALL therapy, but usually an adequate growth catch-up is obtained after cessation of therapy in children who do not receive radiotherapy<sup>105,106</sup>, but with a trend toward reduced final height<sup>107</sup>.

A significant weight gain is seen in up to 40% of children with ALL, primarily reflecting exposure to corticosteroids and reduced physical activity with insulin resistance, hyperglycemia,

and prediabetes, which could indicate the need for dietary modifications and insulin therapy<sup>108–111</sup>. The risk of corticosteroid-induced hyperglycemia is aggravated by asparaginase therapy<sup>112,113</sup>. The prevalence of hyperglycemia during ALL therapy has been reported to be 10% to 20% during treatment with asparaginase and corticosteroids, most frequently in children above 10 years of age, with resolution after cessation or tapering down of these drugs<sup>112–116</sup>. Medication-induced diabetes may be a marker for metabolic disease later in life<sup>116</sup>. Finally, hyperglycemia and obesity both have been associated with reduced event-free survival<sup>117,118</sup>.

Fasting hypoglycemia is common during MTX/thiopurine-based maintenance therapy, especially in children below 6 years of age, but resolves after discontinuation of therapy<sup>119,120</sup>. It may reflect lowered plasma levels of the gluconeogenic amino acids (alanine and glutamine) as well as impaired glycogenolysis or glyconeogenesis<sup>119,121</sup>.

Corticosteroids cause a suppression of the HPA axis with secondary adrenal insufficiency and impaired stress response in nearly all patients, which for some patients may last several months after cessation of corticosteroid therapy irrespective of whether prednisolone or dexamethasone has been used<sup>122</sup>. It may be aggravated by co-administration of fluconazole<sup>122</sup>. Thus, corticosteroid replacement is indicated during the first weeks to months after cessation of corticosteroid therapy, not least during episodes of serious stress unless a stimulation test has shown a normal adrenal response<sup>122,123</sup>. The duration of adrenal insufficiency has been ascribed to variants of the GR gene<sup>124</sup>, but formal genome-wide association analyses are lacking.

### HD-MTX-related nephrotoxicity

Alkalinization and vigorous hydration reduce the risk of significant nephrotoxicity with HD-MTX, but approximately 3% of patients will experience severe renal toxicity that will further compromise MTX clearance<sup>125–128</sup>. The nephrotoxicity is likely to be related to precipitation of MTX crystals in the kidneys and this is partly due to insufficient hydration and alkalinization<sup>129,130</sup>. Plasma creatinine usually peaks within a few days after initiation of the HD-MTX infusion and returns to baseline after a few weeks. Nearly all patients will subsequently tolerate full-dose HD-MTX without recurrent nephrotoxicity<sup>127,128</sup>. Higher doses of folinic acid, adjusted by the plasma MTX levels, are essential to limit the risk of life-threatening myelosuppression and mucositis, but whether over-rescue could increase the risk of relapse remains an unsolved challenge<sup>131–133</sup>. In cases with extremely delayed MTX clearance, glucaripidase may be helpful to degrade MTX by enzymatic cleavage to 2,4-diamino-N10-methyl-ptericoic acid (DAMPA) and glutamate<sup>127,128</sup>, but it does not promote restoration of renal function. Proton pump inhibitors and non-steroidal anti-inflammatory drugs<sup>134–142</sup> as well as foodstuff (for example, licorice<sup>143</sup>) and beverages (with low pH or sweetened with licorice extract) have been suspected to affect the MTX clearance<sup>144</sup>. Since the introduction of 5-HT<sub>3</sub> receptor antagonists, emesis is not a problem during HD-MTX and not linked to acute kidney injury.

Trimethoprim-sulfamethoxazole used as *Pneumocystis jiroveci* prophylaxis during ALL therapy does not seem to interfere with HD-MTX PK<sup>145</sup>.

Several germline DNA variants are associated with MTX clearance, most notably in *SLCO1B1*<sup>146–149</sup>, but none has yet been implemented in HD-MTX dosing strategies or been shown to be associated with extremely delayed MTX clearance.

### Toxicities secondary to asparaginase therapy

Asparaginase causes a range of toxicities due to asparagine depletion and disturbed protein synthesis. These toxicities may occur in up to 20 to 25% of all patients<sup>4</sup> and may lead to discontinuation of asparaginase therapy, which may increase the risk of relapse, not least in the CNS<sup>150,151</sup>.

### Asparaginase-associated allergy

The various asparaginase preparations and recombinant analogs differ in their biologic half-lives (shortest for *Erwinia chrysanthemi*-derived asparaginase and longest for PEG-asparaginase) and in their immunogenicity (lowest for PEG-asparaginase)<sup>152,153</sup>. Asparaginase can induce antibody formation that neutralizes asparaginase with or without (so-called silent inactivation) clinical signs of hypersensitivity<sup>154–156</sup>. Identification of silent inactivation requires measurement of plasma asparaginase activity levels.

The reported frequency of allergic reactions ranges from 3 to 75% depending on the type, dose, route, and duration of asparaginase administration, and allergic reaction primarily occurs after the first or second dose and virtually always is associated with zero asparaginase activity<sup>150,154,157–162</sup>. The reactions range from mild, local reactions to life-threatening systemic responses, including urticaria, symptomatic bronchospasm, edema/angioedema, and hypotension. Premedication with corticosteroid and antihistamines and increased infusion time can reduce allergic symptoms but do not prevent asparaginase inactivation, and thus symptoms of hypersensitivity indicate the need to switch from *E. coli*-derived preparations to *Erwinia* asparaginase (or vice versa)<sup>7,163</sup>. Less immunogenic asparaginase preparations are emerging but are not routinely used in first-line therapy<sup>164–166</sup>.

Allergic-like reactions (for example, vomiting, stomach ache, or rash) with intact asparaginase activity can be seen but do not indicate discontinuation of the drug<sup>7</sup>. Therapeutic drug monitoring can be helpful for differentiating allergy and allergic-like reactions<sup>154</sup>. HLA-DRB1\*07:01 and genetic variations in *GRIA1* have been associated with a higher incidence of hypersensitivity and anti-asparaginase antibodies<sup>167,168</sup>.

### Asparaginase-associated pancreatitis

Asparaginase-associated pancreatitis (AAP) has a reported incidence of 2 to 18% depending on the cumulative asparaginase dose (that is, treatment duration) and toxicity capture strategies but seemingly not on the route of administration<sup>7,158,169–174</sup>. AAP is most often diagnosed within two weeks of asparaginase exposure (median of 11 days with PEG-asparaginase), but the interval may

be longer<sup>175</sup>. The diagnostic criteria defined by the PTWG<sup>7</sup> are similar to those developed for pancreatitis in general<sup>176</sup> and require two of three criteria to be met: (i) abdominal symptoms suggestive of AAP, (ii) characteristic findings of pancreatitis on imaging, and (iii) serum lipase or amylase or both at least three times the UNL, and both enzymes should be measured because of a poor correlation between the two<sup>175</sup>. If imaging shows pancreatic necrosis or hemorrhage and/or the abdominal symptoms and elevated pancreatic enzymes at least three times the UNL persist for more than 72 hours, AAP is classified as severe and otherwise as mild.

Most AAP episodes are accompanied by systemic inflammatory responses (fever, elevated heart rate, elevated respiratory rate, or hypotension) and thus may easily be misinterpreted as sepsis. In addition to transient or permanent discontinuation of asparaginase therapy, treatment of AAP includes appropriate triage, fluid resuscitation, antibiotics (until an infection is ruled out), and monitoring for and treatment of AAP-related complications<sup>177</sup>. The mortality rate is low, but patients systemically affected at AAP diagnosis are at increased risk of developing pseudocysts, acute or persistent diabetes mellitus, and chronic/relapsing pancreatitis<sup>175,178</sup>. Octreotide has been tested in few patients, but the benefit thereof remains to be determined<sup>179,180</sup>.

The risk of a second AAP after re-exposing patients with AAP to asparaginase is almost 50% and does not seem to be significantly lower if the first AAP episode was classified as mild<sup>170,174,175</sup>.

Risk factors for AAP are few, although the incidence is associated with older age. Polymorphisms in *PRSSI*, *SPINK1*, *ASNS*, *ULK2*, *RGS6*, and *CPA2* genes have been associated either with pediatric pancreatitis in general or with AAP<sup>162,174,181,182</sup>, although these associations await validation.

### Hyperlipidemia

Elevated triglycerides and cholesterol occur frequently during ALL therapy and are associated with corticosteroid and asparaginase therapy<sup>7,78,83,183</sup>. However, patients are generally completely unaffected, even when levels are 40 to 50 times the UNL, the association with specific toxicities is very uncertain, and accordingly neither routine measurements nor interventions are recommended<sup>7</sup>.

The hypertriglyceridemia is likely related to an increase in the endogenous hepatic synthesis of very low-density lipoprotein combined with a decreased activity in lipoprotein lipase, an enzyme involved in the removal of triglyceride-rich lipoproteins from the plasma<sup>184</sup>.

The most common preventive measures in cases of hypertriglyceridemia are dietary restrictions (very limited effect), fibrates, insulin infusions, heparin infusions, and in extreme cases plasmapheresis, but there are no data to support that any of these interventions reduces the risk of hypertriglyceridemia-associated toxicities<sup>83,185–189</sup>. In adults with non-malignant disorders, hypertriglyceridemia (above 10 times the UNL) has been associated with an increased risk of acute pancreatitis<sup>185,188,190</sup>, but so

far this has not been replicated in children with ALL<sup>191</sup>. A few studies have indicated associations with development of ON and thrombosis<sup>78,83,95,158,188,192</sup>, but no randomized studies have explored whether lipid-lowering interventions prevent these complications.

### Host genome variant associations

As mentioned above, multiple variants in germline DNA have been associated with the pharmacology of anti-leukemic agents, including the risk of toxicities<sup>6,68,193</sup>, but their individual hazard ratios are generally low (<2.0), the variants are rare or lack validation in independent studies, and treatment alterations according to such variants so far have not been implemented in childhood ALL therapy. The main reasons for our current inability to identify clinically actionable germline variants associated with specific toxicities are lack of sufficient study power (since each toxicity is rare and few trial groups are investigating genotype variation), incomplete toxicity capture, lack of detailed phenotyping (for example, lumping all subtypes and grades of a toxicity), and exploration of single-nucleotide polymorphisms rather than biological pathways. To address these limitations, the PTWG is now collecting phenotypes of several acute toxicities (pancreatitis, ON, and CNS toxicities) in hundreds of patients for each of these toxicities to associate detailed phenotypes with germline DNA variants<sup>175</sup>.

### Leukemia predisposition syndromes

Recent research has identified several germline mutations in genes that play a critical role in hematopoiesis and lymphoid development and that are also frequently somatically mutated in ALL, such as *PAX5*<sup>194,195</sup>, *ETV6*<sup>196,197</sup>, *RUNX1*<sup>198</sup>, and *IKZF1*<sup>199</sup>, which align with the findings of high subtype concordance in familial cases of ALL<sup>195,197,200,201</sup>. This indicates that pure familial ALL syndromes may constitute a substantial part of ALL etiology and that more such syndromes are expected to emerge in parallel with a growing number of patients being germline-sequenced and with a deeper understanding of the impact of coding and non-coding DNA interactions<sup>196</sup>. However, the impact of such germline DNA mutations on toxicities, not least those involving the bone marrow and immune system, remains to be determined. The risk of second malignant neoplasms may also be increased when childhood ALL arises due to a predisposition syndrome. Unusual acute toxicities and second malignant neoplasms therefore should lead to clinical suspicion of an underlying syndrome<sup>202</sup>.

Down syndrome is the most frequent known germline mutation predisposing to ALL and is associated with enhanced gastrointestinal toxicity<sup>203</sup>. However, reducing treatment intensity may also increase the risk of relapse<sup>204</sup> and should be considered only in case of excessive toxicity in the 10 to 15% of Down syndrome-ALL patients who harbor high hyperdiploidy or an *ETV6-RUNX1* translocation, since these subsets have a superior cure rate<sup>205</sup>.

Several other ALL-predisposing syndromes such as Li-Fraumeni, ataxia telangiectasia, Nijmegen breakage, biallelic mismatch repair, and Fanconi anemia can also exhibit syndrome-related toxicities when exposed to DNA-damaging anti-cancer agents or radiotherapy<sup>206–209</sup>. In such cases, a reduction of DNA-damaging



drug doses must be considered on an individual basis, and at least for ataxia telangiectasia and Nijmegen breakage dose reduction may not be associated with an increased risk of relapse<sup>210</sup>. In contrast, thiopurine-based maintenance therapy may be less efficient in patients with biallelic mismatch repair deficiency, since this pathway is critical for thiopurine cytotoxicity<sup>211</sup>.

### Future research

The low frequency and poor definitions of most of the listed organ toxicities have hampered their in-depth exploration, including the impact of specific drug dosing regimens, and identification of clear risk factors for certain phenotypic subsets. The recent PTWG consensus definitions of 14 of these toxicities have provided a platform for international collaboration on these issues<sup>7</sup>. The results from the first of such explorations demonstrate its feasibility<sup>175</sup> and may allow exploration of the association between risk factors, including host DNA variants, in well-defined phenotypic subsets and provide evidence-based guidelines for treatment adaptation. Furthermore, the association of these acute toxicities with the risk of long-term organ toxicities (for example, dementia, diabetes, arthrosis, and chronic pancreatitis) remains to be mapped. Currently, event-free survival measures encompass death during induction, resistance to first-line therapy, relapse of leukemia, non-leukemic death during clinical remission, and development of a second cancer. However, many patients with a late relapse or a second cancer have a fair chance of cure<sup>212,213</sup>, whereas chronic toxicities are generally irreversible and challenge patients' ability to live a normal adult life<sup>214</sup>. This calls for new endpoint measures that include both survival and quality of life, which will require common strategies for toxicity capture and

registration, and international collaboration to identify host genome variants and exposures (for example, anti-leukemic treatment, co-medication, and diet) associated with the risk of specific toxicities, but it also demands the development of a joint endpoint scoring system that encompasses OS as well as severe toxicities, both acute and long-term.

### Abbreviations

6-MP, 6-mercaptopurine; AAP, asparaginase-associated pancreatitis; ALL, acute lymphoblastic leukemia; CNS, central nervous system; HD, high dose; HPA, hypothalamic-pituitary-adrenal; hSCT, hematopoietic stem cell transplantation; MRI, magnetic resonance imaging; MTX, methotrexate; NMDAR, N-methyl-D-aspartate receptor ON, osteonecrosis; OS, overall survival; PEG, polyethylene glycol; PRES, posterior reversible encephalopathy syndrome; PTWG, Ponte di Legno Toxicity Working Group; SLS, stroke-like syndrome; SOS, sinusoidal obstruction syndrome; TE, thromboembolism; UNL, upper normal limit.

### Competing interests

The authors declare that they have no competing interests.

### Grant information

This work was supported by the Danish Cancer Society and the Danish Childhood Cancer Foundation.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

### References



- Stary J, Hrušák O: **Recent advances in the management of pediatric acute lymphoblastic leukemia [version 1; referees: 2 approved]**. *F1000Res*. 2016; 5(F1000 Faculty Rev): 2635.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pui CH, Yang JJ, Hunger SP, *et al.*: **Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration**. *J Clin Oncol*. 2015; 33(27): 2938–48.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lund B, Åsberg A, Heyman M, *et al.*: **Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia**. *Pediatr Blood Cancer*. 2011; 56(4): 551–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Frandsen TL, Heyman M, Abrahamsson J, *et al.*: **Complying with the European Clinical Trials directive while surviving the administrative pressure - an alternative approach to toxicity registration in a cancer trial**. *Eur J Cancer*. 2014; 50(2): 251–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mullighan CG: **The molecular genetic makeup of acute lymphoblastic leukemia**. *Hematology Am Soc Hematol Educ Program*. 2012; 2012: 389–96.  
[PubMed Abstract](#)
- Moriyama T, Relling MV, Yang JJ: **Inherited genetic variation in childhood acute lymphoblastic leukemia**. *Blood*. 2015; 125(26): 3988–95.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Schmiegelow K, Attarbaschi A, Barzilai S, *et al.*: **Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus**. *Lancet Oncol*. 2016; 17(6): e231–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- National Institutes of Health: **Common Terminology Criteria for Adverse Events (CTCAE)**. 2009; (v4.03: June 14, 2010).  
[Reference Source](#)
- de Rojas T, Bautista FJ, Madero L, *et al.*: **The First Step to Integrating Adapted Common Terminology Criteria for Adverse Events for Children**. *J Clin Oncol*. 2016; 34(18): 2196–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rask C, Albertoni F, Schroder H, *et al.*: **Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate**. *Pediatr Hematol Oncol*. 1996; 13(4): 359–67.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Figliolia SL, Oliveira DT, Pereira MC, *et al.*: **Oral mucositis in acute lymphoblastic leukaemia: analysis of 169 paediatric patients**. *Oral Dis*. 2008; 14(8): 761–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Otmani N, Alami R, Hessissen L, *et al.*: **Determinants of severe oral mucositis in paediatric cancer patients: a prospective study**. *Int J Paediatr Dent*. 2011; 21(3): 210–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rathe M, Sorensen GL, Wehner PS, *et al.*: **Chemotherapeutic treatment reduces circulating levels of surfactant protein-D in children with acute lymphoblastic leukemia**. *Pediatr Blood Cancer*. 2017; 64(3): e26253.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Cheng KK, Goggins WB, Lee VW, *et al.*: **Risk factors for oral mucositis in children undergoing chemotherapy: a matched case-control study**. *Oral Oncol*. 2008; 44(11): 1019–25.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ye Y, Carlsson G, Agholme MB, *et al.*: **Pretherapeutic plasma pro- and anti-inflammatory mediators are related to high risk of oral mucositis in pediatric patients with acute leukemia: a prospective cohort study**. *PLoS One*. 2013; 8(5): e64918.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

16. Yang L, Hu X, Xu L: **Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis.** *Tumour Biol.* 2012; **33**(5): 1445–54.  
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Ozdemir N, Celkan T, Bariş S, *et al.*: **DNA repair gene XPD and XRCC1 polymorphisms and the risk of febrile neutropenia and mucositis in children with leukemia and lymphoma.** *Leuk Res.* 2012; **36**(5): 565–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Kuiken NS, Rings EH, Tissing WJ: **Risk analysis, diagnosis and management of gastrointestinal mucositis in pediatric cancer patients.** *Crit Rev Oncol Hematol.* 2015; **94**(1): 87–97.  
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Sonis ST: **The pathobiology of mucositis.** *Nat Rev Cancer.* 2004; **4**(4): 277–84.  
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Sonis ST: **Pathobiology of oral mucositis: novel insights and opportunities.** *J Support Oncol.* 2007; **5**(9 Suppl 4): 3–11.  
[PubMed Abstract](#)
21. Kornblit B, Müller K: **Sensing danger: toll-like receptors and outcome in allogeneic hematopoietic stem cell transplantation.** *Bone Marrow Transplant.* 2016.  
[PubMed Abstract](#) | [Publisher Full Text](#)
22. van Vliet MJ, Harmsen HJ, de Bont ES, *et al.*: **The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis.** *PLoS Pathog.* 2010; **6**(5): e1000879.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Fijlstra M, Ferdous M, Koning AM, *et al.*: **Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model.** *Support Care Cancer.* 2015; **23**(6): 1513–22.  
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Herbers AH, de Haan AF, van der Velden WJ, *et al.*: **Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients.** *Transpl Infect Dis.* 2014; **16**(2): 279–85.  
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Bakhshi S, Padmanjali KS, Arya LS: **Infections in childhood acute lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes.** *Pediatr Hematol Oncol.* 2008; **25**(5): 385–92.  
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Stabell N, Nordal E, Stensvold E, *et al.*: **Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome.** *Scand J Infect Dis.* 2008; **40**(4): 301–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Blijlevens NM, Donnelly JP, DePauw BE: **Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients.** *Bone Marrow Transplant.* 2005; **36**(8): 703–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
28. van der Velden WJ, Blijlevens NM, Feuth T, *et al.*: **Febrile mucositis in haematopoietic SCT recipients.** *Bone Marrow Transplant.* 2009; **43**(1): 55–60.  
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Pontoppidan PL, Jordan K, Carlsen AL, *et al.*: **Associations between gastrointestinal toxicity, micro RNA and cytokine production in patients undergoing myeloablative allogeneic stem cell transplantation.** *Int Immunopharmacol.* 2015; **25**(1): 180–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Schots R, van Riet I, Othman TB, *et al.*: **An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation.** *Bone Marrow Transplant.* 2002; **30**(7): 441–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
31. McNeer JL, Kletzel M, Rademaker A, *et al.*: **Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation.** *Biol Blood Marrow Transplant.* 2010; **16**(3): 350–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Gibson RJ, Keefe DM, Lalla RV, *et al.*: **Systematic review of agents for the management of gastrointestinal mucositis in cancer patients.** *Support Care Cancer.* 2013; **21**(1): 313–26.  
[PubMed Abstract](#) | [Publisher Full Text](#)
33. White MC, Hommers C, Parry S, *et al.*: **Pain management in 100 episodes of severe mucositis in children.** *Paediatr Anaesth.* 2011; **21**(4): 411–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Urbancsek H, Kazar T, Mezes I, *et al.*: **Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiohilus in patients with radiation-induced diarrhoea.** *Eur J Gastroenterol Hepatol.* 2001; **13**(4): 391–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Delia P, Sansotta G, Donato V, *et al.*: **Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation.** *Am J Gastroenterol.* 2002; **97**(8): 2150–2.  
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Osterlund P, Ruotsalainen T, Korpela R, *et al.*: **Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.** *Br J Cancer.* 2007; **97**(8): 1028–34.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. S&D Pharma SK s.r.o: **Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients (FENSY).** NCT02544685.  
[Reference Source](#)
38. Ochs JJ, Bowman WP, Pui CH, *et al.*: **Seizures in childhood lymphoblastic leukaemia patients.** *Lancet.* 1984; **2**(8417–8418): 1422–4.  
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Bond J, Hough R, Moppett J, *et al.*: **'Stroke-like syndrome' caused by intrathecal methotrexate in patients treated during the UKALL 2003 trial.** *Leukemia.* 2013; **27**(4): 954–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
40. de Laat P, Te Winkel ML, Devos AS, *et al.*: **Posterior reversible encephalopathy syndrome in childhood cancer.** *Ann Oncol.* 2011; **22**(2): 472–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Judd LL, Schettler PJ, Brown ES, *et al.*: **Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects.** *Am J Psychiatry.* 2014; **171**(10): 1045–51.  
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Drozdowicz LB, Bostwick JM: **Psychiatric adverse effects of pediatric corticosteroid use.** *Mayo Clin Proc.* 2014; **89**(6): 817–34.  
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Waber DP, Carpentieri SC, Klar N, *et al.*: **Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.** *J Pediatr Hematol Oncol.* 2000; **22**(3): 206–13.  
[PubMed Abstract](#)
44. Waber DP, McCabe M, Sebree M, *et al.*: **Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01.** *Pediatr Blood Cancer.* 2013; **60**(11): 1785–91.  
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Halsey C, Buck G, Richards S, *et al.*: **The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI.** *J Hematol Oncol.* 2011; **4**: 42.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. McGrath P, Holewa H: **The emotional consequences of corticosteroid use in hematology: preliminary findings.** *J Psychosoc Oncol.* 2010; **28**(4): 335–50.  
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Stuart FA, Segal TY, Keady S: **Adverse psychological effects of corticosteroids in children and adolescents.** *Arch Dis Child.* 2005; **90**(5): 500–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Balis FM, Lester CM, Chrousos GP, *et al.*: **Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia.** *J Clin Oncol.* 1987; **5**(2): 202–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Mrakotsky CM, Silverman LB, Dahlberg SE, *et al.*: **Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.** *Pediatr Blood Cancer.* 2011; **57**(3): 492–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Teuffel O, Kuster SP, Hunger SP, *et al.*: **Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.** *Leukemia.* 2011; **25**(8): 1232–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
51. **F** Bhojwani D, Sabin ND, Pei D, *et al.*: **Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.** *J Clin Oncol.* 2014; **32**(9): 949–59.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
52. Khan RB, Morris EB, Pui CH, *et al.*: **Long-term outcome and risk factors for uncontrolled seizures after a first seizure in children with hematological malignancies.** *J Child Neurol.* 2014; **29**(6): 774–81.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Rubnitz JE, Relling MV, Harrison PL, *et al.*: **Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia.** *Leukemia.* 1998; **12**(8): 1176–81.  
[PubMed Abstract](#) | [Publisher Full Text](#)
54. **F** Forster VJ, van Delft FW, Baird SF, *et al.*: **Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients.** *Cancer Chemother Pharmacol.* 2016; **78**(5): 1093–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
55. Bernini JC, Fort DW, Griener JC, *et al.*: **Aminophylline for methotrexate-induced neurotoxicity.** *Lancet.* 1995; **345**(8949): 544–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Drachtman RA, Cole PD, Golden CB, *et al.*: **Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity.** *Pediatr Hematol Oncol.* 2002; **19**(5): 319–27.  
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Haykin ME, Gorman M, van Hoff J, *et al.*: **Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.** *J Neurooncol.* 2006; **76**(2): 153–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Kim SJ, Im SA, Lee JW, *et al.*: **Predisposing factors of posterior reversible encephalopathy syndrome in acute childhood leukemia.** *Pediatr Neurol.* 2012; **47**(6): 436–42.  
[PubMed Abstract](#) | [Publisher Full Text](#)
59. **F** Khan RB, Sadighi ZS, Zabrowski J, *et al.*: **Imaging Patterns and Outcome of Posterior Reversible Encephalopathy Syndrome During Childhood Cancer**

- Treatment.** *Pediatr Blood Cancer.* 2016; **63**(3): 523–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
60. Ulanntinon S, Tzuang D, Dahl G, *et al.*: **Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone.** *Pediatrics.* 2010; **125**(5): e1241–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Wolf VL, Lupo PJ, Lotze TE: **Pediatric acute transverse myelitis overview and differential diagnosis.** *J Child Neurol.* 2012; **27**(11): 1426–36.  
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Yavuz H, Cakir M: **Transverse myelopathy: an initial presentation of acute leukemia.** *Pediatr Neurol.* 2001; **24**(5): 382–4.  
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Schwenn MR, Blattner SR, Lynch E, *et al.*: **HIC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.** *J Clin Oncol.* 1991; **9**(1): 133–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
64. **F** Diouf B, Crews KR, Lew G, *et al.*: **Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.** *JAMA.* 2015; **313**(8): 815–23.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
65. Addington J, Freimer M: **Chemotherapy-induced peripheral neuropathy: an update on the current understanding [version 1; referees: 2 approved].** *F1000Res.* 2016; **5**: pii: F1000 Faculty Rev-1466.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. Nishikawa T, Kawakami K, Kumamoto T, *et al.*: **Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.** *J Pediatr Hematol Oncol.* 2008; **30**(7): 519–21.  
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Graf WD, Chance PF, Lensch MW, *et al.*: **Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.** *Cancer.* 1996; **77**(7): 1356–62.  
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Davidsen ML, Dalhoff K, Schmiegelow K: **Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.** *J Pediatr Hematol Oncol.* 2008; **30**(11): 831–49.  
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Venkatakrishnan K, von Molke LL, Greenblatt DJ: **Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.** *Clin Pharmacokinet.* 2000; **38**(2): 111–80.  
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Egelbakin A, Ferguson MJ, MacGill EA, *et al.*: **Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.** *Pediatr Blood Cancer.* 2011; **56**(3): 361–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Mitchell CD, Richards SM, Kinsey SE, *et al.*: **Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.** *Br J Haematol.* 2005; **129**(6): 734–45.  
[PubMed Abstract](#) | [Publisher Full Text](#)
72. **F** Halton J, Gaboury I, Grant R, *et al.*: **Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program.** *J Bone Miner Res.* 2009; **24**(7): 1326–34.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
73. **F** Vrooman LM, Stevenson KE, Supko JG, *et al.*: **Postinduction dexamethasone and individualized dosing of *Escherichia Coli* L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.** *J Clin Oncol.* 2013; **31**(9): 1202–10.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
74. **F** den Hoed MA, Pluijm SM, te Winkel ML, *et al.*: **Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia.** *Haematologica.* 2015; **100**(12): 1564–70.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
75. Wilson CL, Ness KK: **Bone mineral density deficits and fractures in survivors of childhood cancer.** *Curr Osteoporos Rep.* 2013; **11**(4): 329–37.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
76. Toft N, Birgens H, Abrahamsson J, *et al.*: **Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.** *Eur J Haematol.* 2016; **96**(2): 160–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Kuhlen M, Moldovan A, Krull K, *et al.*: **Osteonecrosis in paediatric patients with acute lymphoblastic leukaemia treated on Co-ALL-07-03 trial: a single centre analysis.** *Klin Padiatr.* 2014; **226**(3): 154–60.  
[PubMed Abstract](#) | [Publisher Full Text](#)
78. **F** Kawedia JD, Kaste SC, Pei D, *et al.*: **Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.** *Blood.* 2011; **117**(8): 2340–7; quiz 2556.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
79. **F** Mattano LA Jr, Devidas M, Nachman JB, *et al.*: **Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.** *Lancet Oncol.* 2012; **13**(9): 906–15.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
80. Kunstreich M, Kummer S, Laws HJ, *et al.*: **Osteonecrosis in children with acute lymphoblastic leukemia.** *Haematologica.* 2016; **101**(11): 1295–305.  
[PubMed Abstract](#) | [Publisher Full Text](#)
81. te Winkel ML, Pieters R, Hop WC, *et al.*: **Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia.** *J Clin Oncol.* 2011; **29**(31): 4143–50.  
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Girard P, Auquier P, Barlogis V, *et al.*: **Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood.** *Haematologica.* 2013; **98**(7): 1089–97.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. Bhojwani D, Darbandi R, Pei D, *et al.*: **Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia.** *Eur J Cancer.* 2014; **50**(15): 2685–94.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. **F** Karol SE, Yang W, van Driest SL, *et al.*: **Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia.** *Blood.* 2015; **126**(15): 1770–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
85. **F** Karol SE, Mattano LA Jr, Yang W, *et al.*: **Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.** *Blood.* 2016; **127**(5): 558–64.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
86. **F** Finkelstein Y, Blonquist TM, Vijayanathan V, *et al.*: **A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.** *Pediatr Blood Cancer.* 2016.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
87. **F** Niinimäki T, Harila-Saari A, Niinimäki R: **The diagnosis and classification of osteonecrosis in patients with childhood leukemia.** *Pediatr Blood Cancer.* 2015; **62**(2): 198–203.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
88. **F** Niinimäki T, Niinimäki J, Halonen J, *et al.*: **The classification of osteonecrosis in patients with cancer: validation of a new radiological classification system.** *Clin Radiol.* 2015; **70**(12): 1439–44.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
89. Qureshi A, Mitchell C, Richards S, *et al.*: **Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.** *Br J Haematol.* 2010; **149**(3): 410–3.  
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Grace RF, Dahlberg SE, Neuberger D, *et al.*: **The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.** *Br J Haematol.* 2011; **152**(4): 452–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
91. Santoro N, Colombini A, Silvestri D, *et al.*: **Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience.** *J Pediatr Hematol Oncol.* 2013; **35**(5): 348–55.  
[PubMed Abstract](#) | [Publisher Full Text](#)
92. Caruso V, Iacoviello L, Di Castelnuovo A, *et al.*: **Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.** *Blood.* 2006; **108**(7): 2216–22.  
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Tuckuviene R, Ranta S, Albertsen BK, *et al.*: **Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study.** *J Thromb Haemost.* 2016; **14**(3): 485–94.  
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Farinasso L, Bertorello N, Garbarini L, *et al.*: **Risk factors of central venous lines-related thrombosis in children with acute lymphoblastic leukemia during induction therapy: a prospective study.** *Leukemia.* 2007; **21**(3): 552–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
95. Payne JH, Vora AJ: **Thrombosis and acute lymphoblastic leukaemia.** *Br J Haematol.* 2007; **138**(4): 430–45.  
[PubMed Abstract](#) | [Publisher Full Text](#)
96. **F** De Stefano V, Za T, Ciminello A, *et al.*: **Haemostatic alterations induced by treatment with asparaginases and clinical consequences.** *Thromb Haemost.* 2015; **113**(2): 247–61.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
97. Ranta S, Tuckuviene R, Makiperna A, *et al.*: **Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology.** *Br J Haematol.* 2015; **168**(4): 547–52.  
[PubMed Abstract](#) | [Publisher Full Text](#)
98. **F** Musgrave KM, van Delft FW, Avery PJ, *et al.*: **Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom.** *Br J Haematol.* 2016.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

99. DeLeve LD, Shulman HM, McDonald GB: **Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).** *Semin Liver Dis.* 2002; **22**(1): 27–42.  
[PubMed Abstract](#) | [Publisher Full Text](#)
100. Escherich G, Richards S, Stork LC, *et al.*: **Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.** *Leukemia.* 2011; **25**(6): 953–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
101. Lennard L, Richards S, Cartwright CS, *et al.*: **The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.** *Clin Pharmacol Ther.* 2006; **80**(4): 375–83.  
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Helmy A: **Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome.** *Aliment Pharmacol Ther.* 2006; **23**(1): 11–25.  
[PubMed Abstract](#) | [Publisher Full Text](#)
103. DeLeve LD: **Vascular Liver Disease and the Liver Sinusoidal Endothelial Cell.** In: *Vascular liver disease.* deLeve LD Garcia-Tsao G; editors. New York: Springer New York; 2011; 25–40.  
[Publisher Full Text](#)
104. Toksvang LN, De Pietri S, Nielsen SN, *et al.*: **Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukaemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.** *Pediatr Blood Cancer.* 2017, in press.
105. Schmiegelow M, Hertz H, Schmiegelow K, *et al.*: **Insulin-like growth factor-I and insulin-like growth factor binding protein-3 during maintenance chemotherapy of acute lymphoblastic leukemia in children.** *J Pediatr Hematol Oncol.* 1999; **21**(4): 268–73.  
[PubMed Abstract](#)
106. Howard SC, Pui CH: **Endocrine complications in pediatric patients with acute lymphoblastic leukemia.** *Blood Rev.* 2002; **16**(4): 225–43.  
[PubMed Abstract](#) | [Publisher Full Text](#)
107. Vandecruys E, Dhooge C, Craen M, *et al.*: **Longitudinal linear growth and final height is impaired in childhood acute lymphoblastic leukemia survivors after treatment without cranial irradiation.** *J Pediatr.* 2013; **163**(1): 268–73.  
[PubMed Abstract](#) | [Publisher Full Text](#)
108. Mohn A, Di Marzio A, Capanna R, *et al.*: **Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia.** *Lancet.* 2004; **363**(9403): 127–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
109. White J, Flohr JA, Winter SS, *et al.*: **Potential benefits of physical activity for children with acute lymphoblastic leukaemia.** *Pediatr Rehabil.* 2005; **8**(1): 53–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
110. Esbenschade AJ, Simmons JH, Friedman DL: **BMI alterations during treatment of childhood ALL-response.** *Pediatr Blood Cancer.* 2012; **58**(6): 1000.  
[PubMed Abstract](#) | [Publisher Full Text](#)
111. Chow EJ, Pihoker C, Friedman DL, *et al.*: **Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia.** *Pediatr Blood Cancer.* 2013; **60**(4): 621–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
112. Pui CH, Burghen GA, Bowman WP, *et al.*: **Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone.** *J Pediatr.* 1981; **99**(1): 46–50.  
[PubMed Abstract](#) | [Publisher Full Text](#)
113. Lowas S, Malempati S, Marks D: **Body mass index predicts insulin resistance in survivors of pediatric acute lymphoblastic leukemia.** *Pediatr Blood Cancer.* 2009; **53**(1): 58–63.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Baillargeon J, Langevin AM, Mullins J, *et al.*: **Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia.** *Pediatr Blood Cancer.* 2005; **45**(7): 960–3.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Koltin D, Sung L, Naqvi A, *et al.*: **Medication induced diabetes during induction in pediatric acute lymphoblastic leukemia: prevalence, risk factors and characteristics.** *Support Care Cancer.* 2012; **20**(9): 2009–15.  
[PubMed Abstract](#) | [Publisher Full Text](#)
116. **Y**eshayahu Y, Koltin D, Hamilton J, *et al.*: **Medication-induced diabetes during induction treatment for ALL, an early marker for future metabolic risk?** *Pediatr Diabetes.* 2015; **16**(2): 104–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
117. Sonabend RY, McKay SV, Okcu MF, *et al.*: **Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia.** *J Pediatr.* 2009; **155**(1): 73–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
118. Butturini AM, Dorey FJ, Lange BJ, *et al.*: **Obesity and outcome in pediatric acute lymphoblastic leukemia.** *J Clin Oncol.* 2007; **25**(15): 2063–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
119. Halonen P, Salo MK, Schmiegelow K, *et al.*: **Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia.** *Acta Paediatr.* 2003; **92**(1): 37–42.  
[PubMed Abstract](#) | [Publisher Full Text](#)
120. Bay A, Oner AF, Cesur Y, *et al.*: **Symptomatic hypoglycemia: an unusual side effect of oral purine analogues for treatment of ALL.** *Pediatr Blood Cancer.* 2006; **47**(3): 330–1.  
[PubMed Abstract](#) | [Publisher Full Text](#)
121. Trelinska J, Fendler W, Szadkowska A, *et al.*: **Hypoglycemia and glycemic variability among children with acute lymphoblastic leukemia during maintenance therapy.** *Leuk Lymphoma.* 2011; **52**(9): 1704–10.  
[PubMed Abstract](#) | [Publisher Full Text](#)
122. **F**ordijn MS, Rensen N, Gemke RJ, *et al.*: **Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.** *Cochrane Database Syst Rev.* 2015; **8**: CD008727.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
123. **F** Salem MA, Tantawy AA, El Sedfy HH, *et al.*: **A prospective study of the hypothalamic-pituitary-adrenal axis in children with acute lymphoblastic leukemia receiving chemotherapy.** *Hematology.* 2015; **20**(6): 320–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
124. de Ruitter RD, Gordijn MS, Gemke RJ, *et al.*: **Adrenal insufficiency during treatment for childhood acute lymphoblastic leukemia is associated with glucocorticoid receptor polymorphisms ER22/23EK and BclI.** *Haematologica.* 2014; **99**(8): e136–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
125. Skärby T, Jönsson P, Hjorth L, *et al.*: **High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).** *Cancer Chemother Pharmacol.* 2003; **51**(4): 311–20.  
[PubMed Abstract](#)
126. **F** Christensen AM, Pauley JL, Molinelli AR, *et al.*: **Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.** *Cancer.* 2012; **118**(17): 4321–30.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
127. Widemann BC, Schwartz S, Jayaprakash N, *et al.*: **Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.** *Pharmacotherapy.* 2014; **34**(5): 427–39.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
128. Svahn T, Mellgren K, Harila-Saari A, *et al.*: **Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.** *Pediatr Blood Cancer.* 2016.  
[PubMed Abstract](#) | [Publisher Full Text](#)
129. Sand TE, Jacobsen S: **Effect of urine pH and flow on renal clearance of methotrexate.** *Eur J Clin Pharmacol.* 1981; **19**(6): 453–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
130. **F** Gameau AP, Riopel J, Isenring P: **Acute Methotrexate-Induced Crystal Nephropathy.** *N Engl J Med.* 2015; **373**(7): 2691–3.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
131. Skärby TV, Anderson H, Heldrup J, *et al.*: **High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.** *Leukemia.* 2006; **20**(11): 1955–62.  
[PubMed Abstract](#) | [Publisher Full Text](#)
132. Cohen IJ: **Challenging the clinical relevance of folinic acid over rescue after high dose methotrexate (HDMTX).** *Med Hypotheses.* 2013; **81**(5): 942–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
133. Mikkelsen TS, Mamoudu AD, Tuckuviene R, *et al.*: **Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.** *Pediatr Blood Cancer.* 2014; **61**(2): 297–301.  
[PubMed Abstract](#) | [Publisher Full Text](#)
134. Treon SP, Chabner BA: **Concepts in use of high-dose methotrexate therapy.** *Clin Chem.* 1996; **42**(8 Pt 2): 1322–9.  
[PubMed Abstract](#)
135. Widemann BC, Adamson PC: **Understanding and managing methotrexate nephrotoxicity.** *Oncologist.* 2006; **11**(6): 694–703.  
[PubMed Abstract](#) | [Publisher Full Text](#)
136. Suzuki K, Doki K, Homma M, *et al.*: **Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.** *Br J Clin Pharmacol.* 2009; **67**(1): 44–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
137. Joerger M, Huitema AD, van den Bongard HJ, *et al.*: **Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.** *Br J Clin Pharmacol.* 2006; **62**(1): 71–80.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
138. Bauters TG, Verlooy J, Robays H, *et al.*: **Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report.** *Pharm World Sci.* 2008; **30**(4): 316–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
139. Ronchera CL, Hernández T, Peris JE, *et al.*: **Pharmacokinetic interaction between high-dose methotrexate and amoxicillin.** *Ther Drug Monit.* 1993; **15**(5): 375–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
140. Thyss A, Milano G, Kubar J, *et al.*: **Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen.** *Lancet.* 1986; **1**(8475): 256–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
141. de Miguel D, García-Suárez J, Martín Y, *et al.*: **Severe acute renal failure**

- following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. *Nephrol Dial Transplant*. 2008; 23(12): 3762–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
142. Loue C, Garnier N, Bertrand Y, *et al.*: High methotrexate exposure and toxicity in children with t(9;22) positive acute lymphoblastic leukaemia treated with imatinib. *J Clin Pharm Ther*. 2015.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
143. Lin SP, Tsai SY, Hou YC, *et al.*: Glycyrrhizin and licorice significantly affect the pharmacokinetics of methotrexate in rats. *J Agric Food Chem*. 2009; 57(5): 1854–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
144. Santucci R, Levêque D, Herbrecht R: Cola beverage and delayed elimination of methotrexate. *Br J Clin Pharmacol*. 2010; 70(5): 762–4.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
145. Watts CS, Sciasci JN, Pauley JL, *et al.*: Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. *J Pediatr Hematol Oncol*. 2016; 38(6): 449–52.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
146. Treviño LR, Shimasaki N, Yang W, *et al.*: Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. *J Clin Oncol*. 2009; 27(35): 5972–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
147. Gregers J, Christensen IJ, Dalhoff K, *et al.*: The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. *Blood*. 2010; 115(23): 4671–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
148. Mikkelsen TS, Thorn CF, Yang JJ, *et al.*: PharmGKB summary: methotrexate pathway. *Pharmacogenet Genomics*. 2011; 21(10): 679–86.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
149. Ramsey LB, Panetta JC, Smith C, *et al.*: Genome-wide study of methotrexate clearance replicates *SLCO1B1*. *Blood*. 2013; 121(6): 898–904.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
150. Silverman LB, Gelber RD, Dalton VK, *et al.*: Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. *Blood*. 2001; 97(5): 1211–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
151. Sirvent N, Suciuc S, Rialland X, *et al.*: Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881. *Eur J Cancer*. 2011; 47(2): 239–47.  
[PubMed Abstract](#) | [Publisher Full Text](#)
152. Asselin BL, Whitin JC, Coppola DJ, *et al.*: Comparative pharmacokinetic studies of three asparaginase preparations. *J Clin Oncol*. 1993; 11(9): 1780–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
153. Albertsen BK, Schroder H, Ingerslev J, *et al.*: Comparison of intramuscular therapy with *Erwinia* asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. *Br J Haematol*. 2001; 115(4): 983–90.  
[PubMed Abstract](#) | [Publisher Full Text](#)
154. Liu C, Kawedia JD, Cheng C, *et al.*: Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. *Leukemia*. 2012; 26(11): 2303–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
155. Fernandez CA, Smith C, Yang W, *et al.*: Genome-wide analysis links *NFATC2* with asparaginase hypersensitivity. *Blood*. 2015; 126(1): 69–75.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
156. van der Sluis IM, Vrooman LM, Pieters R, *et al.*: Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. *Haematologica*. 2016; 101(3): 279–85.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
157. Wang B, Relling MV, Storm MC, *et al.*: Evaluation of immunologic crossreaction of anti-asparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. *Leukemia*. 2003; 17(8): 1583–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
158. Tong WH, Pieters R, de Groot-Kruseman HA, *et al.*: The toxicity of very prolonged courses of PEGasparaginase or *Erwinia* asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia. *Haematologica*. 2014; 99(11): 1716–21.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
159. Silverman LB, Supko JG, Stevenson KE, *et al.*: Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. *Blood*. 2010; 115(7): 1351–3.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
160. Henriksen LT, Harila-Saari A, Ruud E, *et al.*: PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol. *Pediatr Blood Cancer*. 2015; 62(3): 427–33.  
[PubMed Abstract](#) | [Publisher Full Text](#)
161. Vrooman LM, Kirov II, Dreyer ZE, *et al.*: Activity and Toxicity of Intravenous *Erwinia* Asparaginase Following Allergy to *E. coli*-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. *Pediatr Blood Cancer*. 2016; 63(2): 228–33.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
162. Liu C, Yang W, Devidas M, *et al.*: Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. *J Clin Oncol*. 2016; 34(18): 2133–40.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
163. Ko RH, Jones TL, Radvinsky D, *et al.*: Allergic reactions and anti-asparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report. *Cancer*. 2015; 121(23): 4205–11.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
164. Offman MN, Krol M, Patel N, *et al.*: Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. *Blood*. 2011; 117(5): 1614–21.  
[PubMed Abstract](#) | [Publisher Full Text](#)
165. Domenech C, Thomas X, Chabaud S, *et al.*: L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. *Br J Haematol*. 2011; 153(1): 58–65.  
[PubMed Abstract](#) | [Publisher Full Text](#)
166. Kumar S, Prabhu AA, Dasu VV, *et al.*: Batch and fed-batch bioreactor studies for the enhanced production of glutaminase-free L-asparaginase from *Pectobacterium carotovorum* MTCC 1428. *Prep Biochem Biotechnol*. 2017; 47(1): 74–80.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
167. Chen SH, Pei D, Yang W, *et al.*: Genetic variations in *GRIA1* on chromosome 5q33 related to asparaginase hypersensitivity. *Clin Pharmacol Ther*. 2010; 88(2): 191–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
168. Fernandez CA, Smith C, Yang W, *et al.*: *HLA-DRB1\*07:01* is associated with a higher risk of asparaginase allergies. *Blood*. 2014; 124(8): 1266–76.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
169. Knoderer HM, Robarge J, Flockhart DA: Predicting asparaginase-associated pancreatitis. *Pediatr Blood Cancer*. 2007; 49(5): 634–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
170. Kearney SL, Dahlberg SE, Levy DE, *et al.*: Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. *Pediatr Blood Cancer*. 2009; 53(2): 162–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
171. Samarasinghe S, Dhir S, Slack J, *et al.*: Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. *Br J Haematol*. 2013; 162(5): 710–3.  
[PubMed Abstract](#) | [Publisher Full Text](#)
172. Raja RA, Schmiegelow K, Albertsen BK, *et al.*: Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. *Br J Haematol*. 2014; 165(1): 126–33.  
[PubMed Abstract](#) | [Publisher Full Text](#)
173. Place AE, Stevenson KE, Vrooman LM, *et al.*: Intravenous pegylated asparaginase versus intramuscular native *Escherichia coli* L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. *Lancet Oncol*. 2015; 16(16): 1677–90.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
174. Wolthers BO, Frandsen TL, Abrahamsson J, *et al.*: Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. *Leukemia*. 2017; 31(2): 325–32.  
[PubMed Abstract](#) | [Publisher Full Text](#)
175. Wolthers BO, Frandsen TL, Baruchel A, *et al.*: Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Report on Clinical Presentation and Outcome. *Blood*. 2016; 128: 585.  
[Reference Source](#)
176. Morinville VD, Husain SZ, Bai H, *et al.*: Definitions of pediatric pancreatitis and survey of present clinical practices. *J Pediatr Gastroenterol Nutr*. 2012; 55(3): 261–5.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
177. Forsmark CE, Vege SS, Wilcox CM: Acute Pancreatitis. *N Engl J Med*. 2016; 375(20): 1972–81.  
[PubMed Abstract](#) | [Publisher Full Text](#)
178. Spraker HL, Spyridis GP, Pui CH, *et al.*: Conservative management of pancreatic pseudocysts in children with acute lymphoblastic leukemia. *J Pediatr Hematol Oncol*. 2009; 31(12): 957–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
179. Wu SF, Chen AC, Peng CT, *et al.*: Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2008; 51(6): 824–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
180. Tokimasa S, Yamato K: Does octreotide prevent L-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia? *Br J Haematol*. 2012; 157(3): 381–2.  
[PubMed Abstract](#) | [Publisher Full Text](#)
181. Ben Tanfous M, Sharif-Askari B, Ceppi F, *et al.*: Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. *Clin Cancer Res*. 2015; 21(2): 329–34.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

182. **F** Kumar S, Ooi CY, Werlin S, *et al.*: **Risk Factors Associated With Pediatric Acute Recurrent and Chronic Pancreatitis: Lessons From INSPPIRE.** *JAMA Pediatr.* 2016; **170**(6): 562–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
183. Blackett PR, Koren E, Blackstock R, *et al.*: **Hyperlipidemia in acute lymphoblastic leukemia.** *Ann Clin Lab Sci.* 1984; **14**(2): 123–9.  
[PubMed Abstract](#)
184. Hoogerbrugge N, Jansen H, Hoogerbrugge PM: **Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity.** *Leukemia.* 1997; **11**(8): 1377–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
185. Cremer P, Lakomek M, Beck W, *et al.*: **The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia.** *Eur J Pediatr.* 1988; **147**(1): 64–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
186. Dietel V, Buhrdel P, Hirsch W, *et al.*: **Cerebral sinus occlusion in a boy presenting with asparaginase-induced hypertriglyceridemia.** *Klin Padiatr.* 2007; **219**(2): 95–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
187. Kfoury-Baz EM, Nassar RA, Taniou RF, *et al.*: **Plasmapheresis in asparaginase-induced hypertriglyceridemia.** *Transfusion.* 2008; **48**(6): 1227–30.  
[PubMed Abstract](#) | [Publisher Full Text](#)
188. Cohen H, Bielorai B, Harats D, *et al.*: **Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.** *Pediatr Blood Cancer.* 2010; **54**(5): 703–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
189. Solano-Páez P, Villegas JA, Colomer I, *et al.*: **L-Asparaginase and steroids-associated hypertriglyceridemia successfully treated with plasmapheresis in a child with acute lymphoblastic leukemia.** *J Pediatr Hematol Oncol.* 2011; **33**(3): e122–4.  
[PubMed Abstract](#) | [Publisher Full Text](#)
190. Yadav D, Pitchumoni CS: **Issues in hyperlipidemic pancreatitis.** *J Clin Gastroenterol.* 2003; **36**(1): 54–62.  
[PubMed Abstract](#) | [Publisher Full Text](#)
191. Raja RA, Schmiegelow K, Sorensen DN, *et al.*: **Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.** *Pediatr Blood Cancer.* 2017; **64**(1): 32–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
192. Powell C, Chang C, Gershwin ME: **Current concepts on the pathogenesis and natural history of steroid-induced osteonecrosis.** *Clin Rev Allergy Immunol.* 2011; **41**(1): 102–13.  
[PubMed Abstract](#) | [Publisher Full Text](#)
193. Relling MV, Ramsey LB: **Pharmacogenomics of acute lymphoid leukemia: new insights into treatment toxicity and efficacy.** *Hematology Am Soc Hematol Educ Program.* 2013; **2013**: 126–30.  
[PubMed Abstract](#) | [Publisher Full Text](#)
194. Hyde RK, Liu PP: **Germline PAX5 mutations and B cell leukemia.** *Nat Genet.* 2013; **45**(10): 1104–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
195. Shah S, Schrader KA, Waanders E, *et al.*: **A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.** *Nat Genet.* 2013; **45**(10): 1226–31.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
196. **F** Moriyama T, Metzger ML, Wu G, *et al.*: **Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.** *Lancet Oncol.* 2015; **16**(16): 1659–66.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
197. **F** Topka S, Vijai J, Walsh MF, *et al.*: **Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.** *PLoS Genet.* 2015; **11**(6): e1005262.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
198. Liew E, Owen C: **Familial myelodysplastic syndromes: a review of the literature.** *Haematologica.* 2011; **96**(10): 1536–42.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
199. Churchman M, Qian M, Zhang R, *et al.*: **Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia.** *Blood.* 2016; **128**(22): LBA–2.  
[Reference Source](#)
200. Schmiegelow K, Lausten Thomsen U, Baruchel A, *et al.*: **High concordance of subtypes of childhood acute lymphoblastic leukemia within families: lessons from sibships with multiple cases of leukemia.** *Leukemia.* 2012; **26**(4): 675–81.  
[PubMed Abstract](#) | [Publisher Full Text](#)
201. **F** Zhang MY, Churpek JE, Keel SB, *et al.*: **Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.** *Nat Genet.* 2015; **47**(2): 180–5.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
202. Schmiegelow K: **Treatment-related toxicities in children with acute lymphoblastic leukaemia predisposition syndromes.** *Eur J Med Genet.* 2016; **59**(12): 654–60.  
[PubMed Abstract](#) | [Publisher Full Text](#)
203. Buitenkamp TD, Mathôt RA, de Haas V, *et al.*: **Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.** *Haematologica.* 2010; **95**(7): 1106–13.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
204. Bohnstedt C, Levinsen M, Rosthøj S, *et al.*: **Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia.** *Leukemia.* 2013; **27**(4): 866–70.  
[PubMed Abstract](#) | [Publisher Full Text](#)
205. **F** Buitenkamp TD, Izraeli S, Zimmermann M, *et al.*: **Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.** *Blood.* 2014; **123**(1): 70–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
206. Borriello A, Locasciulli A, Bianco AM, *et al.*: **A novel Leu153Ser mutation of the Fanconi anemia FANCD2 gene is associated with severe chemotherapy toxicity in a pediatric T-cell acute lymphoblastic leukemia.** *Leukemia.* 2007; **21**(1): 72–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
207. Wimmer K, Kratz CP, Vasen HF, *et al.*: **Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD).** *J Med Genet.* 2014; **51**(6): 355–65.  
[PubMed Abstract](#) | [Publisher Full Text](#)
208. **F** Bougeard G, Renaux-Petel M, Flaman JM, *et al.*: **Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.** *J Clin Oncol.* 2015; **33**(21): 2345–52.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
209. **F** Schoenaker MH, Suarez F, Szczepanski T, *et al.*: **Treatment of acute leukemia in children with ataxia telangiectasia (A-T).** *Eur J Med Genet.* 2016; **59**(12): 641–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
210. Bienemann K, Burkhardt B, Modlich S, *et al.*: **Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia telangiectasia or Nijmegen-breakage syndrome): a retrospective survey.** *Br J Haematol.* 2011; **155**(4): 468–76.  
[PubMed Abstract](#) | [Publisher Full Text](#)
211. Karran P, Attard N: **Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer.** *Nat Rev Cancer.* 2008; **8**(1): 24–36.  
[PubMed Abstract](#) | [Publisher Full Text](#)
212. Schmiegelow K, Levinsen MF, Attarbaschi A, *et al.*: **Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.** *J Clin Oncol.* 2013; **31**(19): 2469–76.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
213. **F** Oskarsson T, Soderhall S, Arvidson J, *et al.*: **Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome.** *Haematologica.* 2016; **101**(1): 68–76.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
214. Armstrong GT, Kawashima T, Leisenring W, *et al.*: **Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study.** *J Clin Oncol.* 2014; **32**(12): 1218–27.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

## Open Peer Review

Current Referee Status:



---

### Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

---

### The referees who approved this article are:

#### Version 1

- 1 **Jan Stary**, Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic  
**Competing Interests:** No competing interests were disclosed.
- 1 **Anne Uytbroeck**, University Hospitals Leuven, Leuven, Belgium  
**Competing Interests:** No competing interests were disclosed.
- 1 **Chris Halsey**, University of Glasgow, Glasgow, UK  
**Competing Interests:** No competing interests were disclosed.